18F-胆碱PET/4D增强CT对甲状旁腺功能亢进的定位价值及与分子特征的相关性
本研究前瞻性纳入44例一线影像阴性或不确定的原发性甲状旁腺功能亢进患者,评估整合18F-胆碱PET/4D增强CT对功能亢进甲状旁腺的定位价值。结果显示整合显像检出率72.7%、灵敏度100%,显著优于单独PET/CT和4D增强CT。胆碱代谢与血钙水平及Ki67表达相关。
要点
- 整合18F-胆碱PET/4D增强CT检出率72.7%,灵敏度100%,显著优于单独PET/CT和4D增强CT
- SUV与血钙水平显著相关,SUVratio与Ki67表达显著相关
- 多因素分析中仅血钙水平与整合显像阳性发现显著相关
核心结论
- 整合18F-胆碱PET/4D增强CT可考虑作为一线影像阴性或不确定的原发性甲状旁腺功能亢进患者的有效检测工具。
- 功能亢进甲状旁腺的胆碱代谢与血钙水平及Ki67表达均相关。
研究设计与样本
- 前瞻性纳入44例一线影像阴性或不确定的原发性甲状旁腺功能亢进患者。
- 同时行18F-胆碱PET/CT与4D增强CT,配准后获得整合18F-胆碱PET/4D增强CT图像,由经验丰富的医师阅片。
- 以组织病理学、实验室检查和多学科随访为标准参照,回顾性计算三种显像方式的检出率和灵敏度。
- 采用免疫组化评估功能亢进甲状旁腺的分子特征。
主要发现
- 整合18F-胆碱PET/4D增强CT在44例患者中32例阳性,检出率72.7%;31例手术患者中31例阳性,灵敏度100%。
- 整合显像检出率和灵敏度显著优于18F-胆碱PET/CT(检出率56.8%,灵敏度80%)和4D增强CT(检出率54.5%,灵敏度74%),p < 0.05。
- SUV与血钙水平存在显著相关。
- 多因素分析中仅血钙水平与整合18F-胆碱PET/4D增强CT发现显著相关。
- SUVratio与Ki67表达显著相关。
关键数值与推荐
- 整合18F-胆碱PET/4D增强CT检出率72.7%(32/44),灵敏度100%(31/31)。
- 18F-胆碱PET/CT检出率56.8%,灵敏度80%。
- 4D增强CT检出率54.5%,灵敏度74%。
- 整合显像与单独PET/CT及4D增强CT比较p < 0.05。
临床怎么用
- 作者认为,对一线影像阴性或不确定的原发性甲状旁腺功能亢进患者,整合18F-胆碱PET/4D增强CT可考虑作为有效的检测工具。
- 原文未据此给出其他临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The localization of hyperfunctioning parathyroid gland(s) (HPTG) in patients with primary hyperparathyroidism (PHPT) with negative or inconclusive first-line imaging is a significant challenge. This study aimed to evaluate the role of integrated 18F-choline PET/4D contrast-enhanced computed tomography (4DCeCT) in these patients, compare its detection rate and sensitivity with those of 18F-choline PET/CT and (4DCeCT), and analyse the association between choline metabolism and morphological, biochemical and molecular parameters of HPTG. METHODS: We prospectively enrolled 44 PHPT patients with negative or inconclusive first-line imaging. 18F-Choline PET/CT and 4DCeCT were performed at the same time, and integrated 18F-choline PET/4DCeCT images were obtained after coregistration. Experienced physicians examined the images. The SUVratio and degree of contrast enhancement were recorded for each positive finding. Histopathology, laboratory and multidisciplinary follow-up were used as the standard of reference. Both the detection rates and sensitivities of the three imaging modalities were calculated retrospectively. Immunohistochemistry was performed to evaluate the molecular profile of HPTGs. RESULTS: 18F-Choline PET/4DCeCT was positive in 32 of 44 patients with PHPT (detection rate 72.7%), and 31 of 31 surgically treated patients (sensitivity 100%). These results were significantly (p < 0.05) better than those of 18F-choline PET/CT (56.8% and 80%, respectively) and those of 4DCeCT (54.5 and 74%, respectively). A significant correlation between SUV and calcium level was found. In a multivariate analysis, only calcium level was significantly associated with 18F-choline PET/4DCeCT findings. SUVratio and Ki67 expression were significantly correlated. CONCLUSION: Integrated 18F-choline PET/4DCeCT should be considered as an effective tool to detect PHPT in patients with negative or inconclusive first-line imaging. Choline metabolism is correlated with both calcium level and Ki67 expression in HPTG.
引用
- Piccardo A, Trimboli P, Rutigliani M, et al. Additional value of integrated 18F-choline PET/4D contrast-enhanced CT in the localization of hyperfunctioning parathyroid glands and correlation with molecular profile. Eur J Nucl Med Mol Imaging. 2018. PMID: 30219964. doi:10.1007/s00259-018-4147-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。